Detection of Isolated Tumor Cells in Bone Marrow Is an Independent Prognostic Factor in Breast Cancer
- 15 September 2003
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (18), 3469-3478
- https://doi.org/10.1200/jco.2003.02.009
Abstract
Purpose: This study was performed to disclose the clinical impact of isolated tumor cell (ITC) detection in bone marrow (BM) in breast cancer. Patients and Methods: BM aspirates were collected from 817 patients at primary surgery. Tumor cells in BM were detected by immunocytochemistry using anticytokeratin antibodies (AE1/AE3). Analyses of the primary tumor included histologic grading, vascular invasion, and immunohistochemical detection of c-erbB-2, cathepsin D, p53, and estrogen receptor (ER)/progesterone receptor (PgR) expression. These analyses were compared with clinical outcome. The median follow-up was 49 months. Results: ITC were detected in 13.2% of the patients. The detection rate rose with increasing tumor size (P = .011) and lymph node involvement (P < .001). Systemic relapse and death from breast cancer occurred in 31.7% and 26.9% of the BM-positive patients versus 13.7% and 10.9% of BM-negative patients, respectively (P < .001). Analyzing node-positive and node-negative patients separately, ITC positivity was associated with poor prognosis in the node-positive group and in node-negative patients not receiving adjuvant therapy (T1N0). In multivariate analysis, ITC in BM was an independent prognostic factor together with node, tumor, and ER/PgR status, histologic grade, and vascular invasion. In separate analysis of the T1N0 patients, histologic grade was independently associated with both distant disease-free survival (DDFS) and breast cancer–specific survival (BCSS), ITC detection was associated with BCSS, and vascular invasion was associated with DDFS. Conclusion: ITC in BM is an independent predictor of DDFS and BCSS. An unfavorable prognosis was observed for node-positive patients and for node-negative patients not receiving systemic therapy. A combination of several independent prognostic factors can classify subgroups of patients into excellent and high-risk prognosis groups.Keywords
This publication has 26 references indexed in Scilit:
- Epithelial Cells in Bone Marrow of Breast Cancer Patients at Time of Primary Surgery: Clinical Outcome During Long-Term Follow-UpJournal of Clinical Oncology, 2001
- Cytokeratin-Positive Cells in the Bone Marrow and Survival of Patients with Stage I, II, or III Breast CancerNew England Journal of Medicine, 2000
- Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up studyThe Lancet, 1999
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.Journal of Clinical Oncology, 1998
- Micrometastatic Breast Cancer Cells in Bone Marrow at Primary Surgery: Prognostic Value in Comparison With Nodal StatusJNCI Journal of the National Cancer Institute, 1996
- Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-upBritish Journal of Cancer, 1994
- Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.Journal of Clinical Oncology, 1991
- Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.BMJ, 1987